Strategic Alliances Promote Test Access and Development
From - Laboratory Industry Report In the early months of 2017, the diagnostic industry has seen several strategic alliances develop. Among the most active companies… . . . read more
![](https://www.g2intelligence.com/wp-content/uploads/2023/04/56181_G2_stock_7.jpg)
In the early months of 2017, the diagnostic industry has seen several strategic alliances develop.
Among the most active companies in February so far is Quest Diagnostics which cut a deal to secure its physician clients access to Veracyte’s Affirma Gene Expression Classifier non-invasive test for diagnosing thyroid cancer and expanded its hospital partnership network to include New York City’s Montefiore Health System. For more news about Veracyte see “Industry Newsmaker: Veracyte, Inc. Scores Big with Percepta and Affirma GEC,” Laboratory Industry Report, Feb. 28, 2017.
Thermo Fisher was also busy starting the month by expanding its year-old deal with Invivoscribe Technologies to co-develop oncology tests for its Ion PGM Dx System to include in vitro assays for the TF Applied Systems Biosystems 3500Dx Genetic Analyzer. A week later, the biotech firm announced a similar deal with Asuragen to co-develop diagnostic kits for the 3500Dx CS2 instrument. Following a busy January (See Diagnostic Deals, Laboratory Industry Report, Jan. 23, 2017), Illumina stayed active announcing a new collaboration with Invivoscribe aimed at developing new in vitro diagnostic assays for the former’s MiSeqDx next generation sequencing platform for the US market.
Trend-wise, collaborations are pairing diagnostics companies with big pharma firms to develop new drug diagnoses and treatments, such as:
- Perthera’s collaboration with Novartis to identify breast and lung cancer patients for pharmaceutical clinical trials;
- The collaboration between Exosome Diagnostics and Merck KgaA on oncology drug development; and
- GenomeDx Biosciences agreement with Astella using the former’s genomic profiling tumor technology to identify patients who are candidates to use the latter’s XTANDI prostate cancer drug.
For a roundup of recent key mergers, acquisitions, alliances, licenses and other strategic transactions see “Diagnostic Deals” in the February issue of Laboratory Industry Report.
Subscribe to view Essential
Start a Free Trial for immediate access to this article